Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Techne

This article was originally published in The Gray Sheet

Executive Summary

Agrees to acquire the primary assets of Genzyme General's Research Products business for about $65.5 mil. - including $24.8 mil. in cash, $17 mil. in Techne common stock and estimated royalties over five years of $23.7 mil. The Research Products unit assets to be acquired generated about $15 mil. in 1997 and consist of a catalog business offering over 350 recombinant proteins, antibodies, and human, mouse, and rat ELISA research kits to over 4,000 customers. Minneapolis-based Techne, maker of cytokine and cytokine-related reagents and assays for use in basic and clinical research, notes the acquisition will extend its network of scientific contacts and collaborations, add product volume and "improve our manufacturing efficiency and marketing and sales effectiveness." Genzyme General is divesting the business as part of a strategy to "focus on growth businesses consistent with our core competencies," and notes that its diagnostics business will continue to produce in vitro diagnostics including rapid tests, clinical chemistry and immunochemistry products. The deal is expected to close by July 1...

You may also be interested in...



EMA Stands By Suspension Of Ranitidine In EU After Re-Examination

Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.

QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate

Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel